Literature DB >> 8535652

Sulphasalazine: mechanism of action in rheumatoid arthritis.

G Smedegård1, J Björk.   

Abstract

Sulphasalazine a drug used for the treatment of rheumatoid arthritis (RA) shows a wide range of biological activities all of which might contribute to the beneficial clinical effect seen during treatment of RA. This review summarizes some of the biological activities and discusses these in context of possible modes of action of the drug. Sulphasalazine has been described as an antibacterial drug, an anti-inflammatory drug or as an immunomodulator. From the reviewed data it is concluded that the effects of sulphasalazine on various immunological processes, are of outstanding importance for its mode of action.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8535652

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  23 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Sulfasalazine: a review of its use in the management of rheumatoid arthritis.

Authors:  Greg L Plosker; Katherine F Croom
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy.

Authors:  Robert C Miller; Daniel G Petereit; Jeff A Sloan; Heshan Liu; James A Martenson; James D Bearden; Ronald Sapiente; Grant R Seeger; Rex B Mowat; Ben Liem; Matthew J Iott; Charles L Loprinzi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-23       Impact factor: 7.038

4.  Disease-modifying anti-rheumatic drugs improve autonomic neuropathy in arthritis: DIANA study.

Authors:  Ashit Syngle; Inderjeet Verma; Pawan Krishan; Nidhi Garg; Vijaita Syngle
Journal:  Clin Rheumatol       Date:  2014-06-15       Impact factor: 2.980

Review 5.  Broadening horizons: the role of ferroptosis in cancer.

Authors:  Xin Chen; Rui Kang; Guido Kroemer; Daolin Tang
Journal:  Nat Rev Clin Oncol       Date:  2021-01-29       Impact factor: 66.675

6.  Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis.

Authors:  Ruud Oerlemans; Josefien Vink; Ben A C Dijkmans; Yehuda G Assaraf; Marjolein van Miltenburg; Joost van der Heijden; Ilan Ifergan; Willem F Lems; Rik J Scheper; Gertjan J L Kaspers; Jacqueline Cloos; Gerrit Jansen
Journal:  Ann Rheum Dis       Date:  2007-01-31       Impact factor: 19.103

7.  Sulfasalazine prevents T-helper 1 immune response by suppressing interleukin-12 production in macrophages.

Authors:  B Y Kang; S W Chung; S Y Im; Y K Choe; T S Kim
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

Review 8.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

9.  Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha.

Authors:  J van der Heijden; M C de Jong; B A C Dijkmans; W F Lems; R Oerlemans; I Kathmann; C G Schalkwijk; G L Scheffer; R J Scheper; G Jansen
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

Review 10.  Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

Authors:  C P Rains; S Noble; D Faulds
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.